Drug Development Pipeline
Vancomycin Inhalation Powder (AeroVanc™)
Vancomycin inhalation powder (AeroVanc™) is an inhaled dry powder version of the antibiotic vancomycin for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) airway infection in people with CF.
Results from a phase 2 study showed that study participants who received AeroVanc™ experienced a significant reduction in MRSA density in their sputum compared with those given a placebo. A phase 3 study to test AeroVanc™ in adults and children over 6 years old with CF is underway.
This program is sponsored by Savara Pharmaceuticals and partially funded by the Cystic Fibrosis Foundation. It is being conducted within the Therapeutics Development Network.
Recent Vancomycin Inhalation Powder (AeroVanc™) Studies
Completed with Results
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More